Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Cidara Therapeutics | 6.42% | $8.01M | $6.92B | 1078.44% | 57 Neutral | |
| Insmed | 5.09% | $6.35M | $44.13B | 179.30% | 53 Neutral | |
| Medpace Holdings | 4.86% | $6.06M | $17.42B | 83.08% | 79 Outperform | |
| Guardant Health | 4.70% | $5.86M | $14.39B | 214.26% | 58 Neutral | |
| Natera | 3.84% | $4.80M | $32.93B | 45.13% | 68 Neutral | |
| Celcuity | 3.65% | $4.56M | $4.68B | 627.70% | 44 Neutral | |
| Tenet Healthcare | 3.44% | $4.29M | $18.86B | 49.75% | 72 Outperform | |
| Nektar Therapeutics | 3.41% | $4.26M | $1.19B | 258.65% | 49 Neutral | |
| Boston Scientific | 3.13% | $3.91M | $145.34B | 9.85% | 79 Outperform | |
| Madrigal Pharmaceuticals | 2.96% | $3.70M | $13.35B | 70.32% | 56 Neutral |